ATXI (Avenue Therapeutics) Accounts Payable: $0.10 Mil (As of Mar. 2026)


ATXI Avenue Therapeutics Inc ATXI
33 GF Score
Price $0.32
! 1 Warning Sign
View Full Analysis

What is Avenue Therapeutics Accounts Payable?

Avenue Therapeutics ATXI 33 Accounts Payable is $0.10 Mil as of Mar. 2026. GuruFocus rates ATXI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Avenue Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $0.10 Mil.

Avenue Therapeutics's quarterly Accounts Payable declined from Sep. 2025 ($0.49 Mil) to Dec. 2025 ($0.09 Mil) but then increased from Dec. 2025 ($0.09 Mil) to Mar. 2026 ($0.10 Mil).

Avenue Therapeutics's annual Accounts Payable increased from Dec. 2023 ($0.08 Mil) to Dec. 2024 ($0.16 Mil) but then declined from Dec. 2024 ($0.16 Mil) to Dec. 2025 ($0.09 Mil).

Avenue Therapeutics Accounts Payable Related Terms

Avenue Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Avenue Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics Accounts Payable Chart

Avenue Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.13 0.08 0.16 0.09

Avenue Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.08 0.49 0.09 0.10
ATXI
33GF Score
Avenue Therapeutics Inc ATXI
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.10 Mil mean?
Avenue Therapeutics (ATXI) has a Accounts Payable of $0.10 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Avenue Therapeutics and its competitors.
Is Avenue Therapeutics' Accounts Payable too high?
Avenue Therapeutics' current Accounts Payable is $0.10 Mil. Overall, Avenue Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' Accounts Payable compare to AGTX and CLSDQ?
Avenue Therapeutics' Accounts Payable of $0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Avenue Therapeutics and its competitors. Avenue Therapeutics's current Accounts Payable is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current Accounts Payable of $0.10 Mil. The current Accounts Payable is $0.10 Mil. Avenue Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current Accounts Payable is $0.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
33GF Score

Get the complete analysis for ATXI

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price